Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference

SAN FRANCISCO--(BUSINESS WIRE)-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced its participation in the American College of Lifestyle Medicine’s (ACLM) 2023 Lifestyle Medicine Annual Conference (LM2023), to be held October 29 to November 1, 2023, in Denver, Colorado. The conference brings together medical professionals, including physicians, healthcare executives, academic faculty, and researchers from across the U.S. and around the world, and seeks to drive the transformation of healthcare by highlighting how shifting lifestyle related behaviors can treat, prevent, and often reverse chronic disease.

Better Therapeutics’ platinum sponsorship of LM2023 reflects the company’s shared commitment to showcasing evidence-based solutions that restore health for those living with chronic conditions.

The company’s focus at the meeting is to showcase AspyreRx, a U.S. Food and Drug Administration (FDA) authorized PDT treatment for adults with type 2 diabetes (T2D). AspyreRx is the first prescription-only digital treatment to provide a proprietary form of cognitive behavioral therapy (CBT) specifically for treating T2D and is designed to overcome many of the limitations of traditional in-person CBT. Attendees will have the opportunity to experience the product firsthand and learn more about its clinical benefits at the Better Therapeutics exhibition booth.

Additionally, Better Therapeutics is hosting a sponsored education session on Tuesday, October 31, 2023 at 5:30pm - 6:30pm MST, with speakers Mark Berman, MD FACLM, Chief Medical Officer, and Elizabeth Pash, PhD, MS, RDN, LDN, Head of Medical Affairs, presenting the clinical data, the mechanism of action, and describing how patients will experience the treatment.

“We are honored to be a platinum sponsor at the LM2023 meeting. This is a gathering of some of the most brilliant minds in the field, and it’s the perfect platform to showcase AspyreRx to an audience that understands the importance of helping patients make meaningful behavior change to improve health outcomes,” said Mark Berman, MD, Chief Medical Office at Better Therapeutics. “We believe our prescription digital therapeutic will revolutionize the way we approach treatment of cardiometabolic diseases, and we’re excited to share it with the healthcare community.”

For more information about LM2023, visit: https://lifestylemedicine.org/project/lm2023/

For more information about AspyreRx, visit: www.aspyrerx.com.

About AspyreRx

AspyreRx (formerly BT-001) was granted marketing authorization by the U.S. Food and Drug Administration (FDA) in July 2023 as the first prescription-only digital therapeutic to treat adults with type 2 diabetes (T2D). AspyreRx is backed by robust data demonstrating clinically meaningful and sustained reduction in A1c as well as improvements in other markers of cardiometabolic health when used up to 180 days. Using proven techniques that target the underlying psychological, behavioral, and cognitive factors that sustain or worsen T2D, AspyreRx is a self-paced, engaging experience that patients can access from their smartphone. It is prescribed by a healthcare provider in 90-day increments, with proprietary CBT delivered digitally in a weekly step-by-step process. Through interactive therapy lessons, skill-building modules, weekly goal setting and tracking, patients connect changes in behavior to improvements in blood sugar and other biometrics. Each step in the experience builds on the prior to enable and reinforce cognitive restructuring, building the emotional resilience and acceptance needed to make enduring changes.

Indications for Use

AspyreRx is a prescription-only digital therapeutic device intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets behavior to aid in the management of type 2 diabetes in patients who are under the care of a healthcare provider. AspyreRx provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address underlying factors that sustain or worsen cardiometabolic diseases. The Company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for T2D, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this press release include, but are not limited to, statements regarding Better Therapeutics’ expectations related to the efficacy and potential benefits of PDTs, including AspyreRx and CBT, and their potential treatment applications and their ability to improve clinical outcomes, beliefs regarding the importance and potential of behavior modification in diabetes treatment and statements related to the needs of people living with T2D, among others. These forward-looking statements are based on the current expectations of the management of Better Therapeutics and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to Better Therapeutics’ business, such as the willingness of the FDA to authorize PDTs, for commercial distribution and insurance companies to reimburse their use, market acceptance of PDTs, including AspyreRx, the risk that the results of previously conducted studies will not be interpreted favorably by the FDA or repeated or observed in ongoing or future studies involving Better Therapeutics’ product candidates and other risks and uncertainties included under the header “Risk Factors” in Better Therapeutics’ quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed with the Securities and Exchange Commission (SEC) on August 9, 2023, and those that are included in any of Better Therapeutics’ subsequent filings with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231026498322/en/